Zentalis Pharmaceuticals Inc expected to post a loss of 71 cents a share - Earnings Preview

Reuters03-05

Zentalis Pharmaceuticals Inc ZNTL.OQ ZNTL.O is expected to show no change in quarterly revenue when it reports results on March 7 (estimated) for the period ending December 31 2024
LSEG's mean analyst estimate for Zentalis Pharmaceuticals Inc is for a loss of 71 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $6.00, above its last closing price of $1.87.

Previous quarterly performance (using preferred earnings measure in US dollars).

QUARTER ENDING	STARMINESMARTESTIMATE®	LSEG IBES ESTIMATE	ACTUAL	BEAT, MET, MISSED	SURPRISE %
Sep. 30 2024	-0.88	-0.91	-0.56	Beat	38.5
Jun. 30 2024	-0.87	-0.84	-1.24	Missed	-47.5
Mar. 31 2024	-0.76	-0.77	0.14	Beat	118.3
Dec. 31 2023	-0.94	-0.92	-0.93	Missed	-1.5
Sep. 30 2023	-0.91	-0.91	-0.79	Beat	13.3
Jun. 30 2023	-1.02	-1.04	-1.85	Missed	-78.3
Mar. 31 2023	-0.98	-1.02	-1.07	Missed	-5
Dec. 31 2022	-1.01	-1.06	-0.92	Beat	13.2

This summary was machine generated March 5 at 11:01 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2517499726?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-05 19:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2517499726","market":"us","top_or_hot":-1,"title":"Zentalis Pharmaceuticals Inc  expected to post a loss of 71 cents a share - Earnings Preview","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Zentalis Pharmaceuticals Inc <zntl.oq> expected to post a loss of 71 cents a share - Earnings Preview </zntl.oq></title></head><body><ul><li><p>Zentalis Pharmaceuticals Inc <span>ZNTL.OQ</span> <span>ZNTL.O</span> is expected to show no change in quarterly revenue when it reports  results on March 7 (estimated) for the period ending December 31 2024</p></li><li></li><li><p>LSEG's mean analyst estimate for Zentalis Pharmaceuticals Inc is for a loss of 71 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy,\" 6 \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $6.00, above its last closing price of $1.87. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-0.88</p></td><td><p>-0.91</p></td><td><p>-0.56</p></td><td><p>Beat</p></td><td><p>38.5</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-0.87</p></td><td><p>-0.84</p></td><td><p>-1.24</p></td><td><p>Missed</p></td><td><p>-47.5</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-0.76</p></td><td><p>-0.77</p></td><td><p>0.14</p></td><td><p>Beat</p></td><td><p>118.3</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-0.94</p></td><td><p>-0.92</p></td><td><p>-0.93</p></td><td><p>Missed</p></td><td><p>-1.5</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-0.91</p></td><td><p>-0.91</p></td><td><p>-0.79</p></td><td><p>Beat</p></td><td><p>13.3</p></td></tr><tr><td><p>Jun. 30 2023</p></td><td><p>-1.02</p></td><td><p>-1.04</p></td><td><p>-1.85</p></td><td><p>Missed</p></td><td><p>-78.3</p></td></tr><tr><td><p>Mar. 31 2023</p></td><td><p>-0.98</p></td><td><p>-1.02</p></td><td><p>-1.07</p></td><td><p>Missed</p></td><td><p>-5</p></td></tr><tr><td><p>Dec. 31 2022</p></td><td><p>-1.01</p></td><td><p>-1.06</p></td><td><p>-0.92</p></td><td><p>Beat</p></td><td><p>13.2</p></td></tr></tbody></table><p>This summary was machine generated March 5 at 11:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zentalis Pharmaceuticals Inc  expected to post a loss of 71 cents a share - Earnings Preview</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZentalis Pharmaceuticals Inc  expected to post a loss of 71 cents a share - Earnings Preview\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-03-05 19:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Zentalis Pharmaceuticals Inc <zntl.oq> expected to post a loss of 71 cents a share - Earnings Preview </zntl.oq></title></head><body><ul><li><p>Zentalis Pharmaceuticals Inc <span>ZNTL.OQ</span> <span>ZNTL.O</span> is expected to show no change in quarterly revenue when it reports  results on March 7 (estimated) for the period ending December 31 2024</p></li><li></li><li><p>LSEG's mean analyst estimate for Zentalis Pharmaceuticals Inc is for a loss of 71 cents per share. </p></li><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy,\" 6 \"hold\" and no \"sell\" or \"strong sell.\"  </p></li><li><p>The mean earnings estimate of analysts was unchanged in the last three months. </p></li><li><p>Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $6.00, above its last closing price of $1.87. </p></li></ul><p>Previous quarterly performance (using preferred earnings measure in US dollars). </p><table><tbody><tr><td><p>QUARTER ENDING</p></td><td><p>STARMINESMARTESTIMATE®</p></td><td><p>LSEG IBES ESTIMATE </p></td><td><p>ACTUAL</p></td><td><p>BEAT, MET, MISSED</p></td><td><p>SURPRISE %</p></td></tr><tr><td><p>Sep. 30 2024</p></td><td><p>-0.88</p></td><td><p>-0.91</p></td><td><p>-0.56</p></td><td><p>Beat</p></td><td><p>38.5</p></td></tr><tr><td><p>Jun. 30 2024</p></td><td><p>-0.87</p></td><td><p>-0.84</p></td><td><p>-1.24</p></td><td><p>Missed</p></td><td><p>-47.5</p></td></tr><tr><td><p>Mar. 31 2024</p></td><td><p>-0.76</p></td><td><p>-0.77</p></td><td><p>0.14</p></td><td><p>Beat</p></td><td><p>118.3</p></td></tr><tr><td><p>Dec. 31 2023</p></td><td><p>-0.94</p></td><td><p>-0.92</p></td><td><p>-0.93</p></td><td><p>Missed</p></td><td><p>-1.5</p></td></tr><tr><td><p>Sep. 30 2023</p></td><td><p>-0.91</p></td><td><p>-0.91</p></td><td><p>-0.79</p></td><td><p>Beat</p></td><td><p>13.3</p></td></tr><tr><td><p>Jun. 30 2023</p></td><td><p>-1.02</p></td><td><p>-1.04</p></td><td><p>-1.85</p></td><td><p>Missed</p></td><td><p>-78.3</p></td></tr><tr><td><p>Mar. 31 2023</p></td><td><p>-0.98</p></td><td><p>-1.02</p></td><td><p>-1.07</p></td><td><p>Missed</p></td><td><p>-5</p></td></tr><tr><td><p>Dec. 31 2022</p></td><td><p>-1.01</p></td><td><p>-1.06</p></td><td><p>-0.92</p></td><td><p>Beat</p></td><td><p>13.2</p></td></tr></tbody></table><p>This summary was machine generated March 5 at 11:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ZNTL","symbol_name":"Zentalis Pharmaceuticals, LLC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250305:nL5N3PO0V9:1","article_id":"2517499726","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2517499726","pubTimestamp":1741172562,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Zentalis Pharmaceuticals Inc  expected to post a loss of71cents a share - Earnings Preview Zentalis Pharmaceuticals Inc ZNTL.OQ ZNTL.O is expected to show no change in quarterly revenue when it report","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"ZNTL":"Zentalis Pharmaceuticals, LLC"},"translate_title":"Zentalis Pharmaceuticals Inc预计每股亏损71美分-收益预览","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ZNTL":0.9},"content_text":"Zentalis Pharmaceuticals Inc  expected to post a loss of 71 cents a share - Earnings Preview Zentalis Pharmaceuticals Inc ZNTL.OQ ZNTL.O is expected to show no change in quarterly revenue when it reports  results on March 7 (estimated) for the period ending December 31 2024LSEG's mean analyst estimate for Zentalis Pharmaceuticals Inc is for a loss of 71 cents per share. The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 5 \"strong buy\" or \"buy,\" 6 \"hold\" and no \"sell\" or \"strong sell.\"  The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $6.00, above its last closing price of $1.87. Previous quarterly performance (using preferred earnings measure in US dollars). QUARTER ENDINGSTARMINESMARTESTIMATE®LSEG IBES ESTIMATE ACTUALBEAT, MET, MISSEDSURPRISE %Sep. 30 2024-0.88-0.91-0.56Beat38.5Jun. 30 2024-0.87-0.84-1.24Missed-47.5Mar. 31 2024-0.76-0.770.14Beat118.3Dec. 31 2023-0.94-0.92-0.93Missed-1.5Sep. 30 2023-0.91-0.91-0.79Beat13.3Jun. 30 2023-1.02-1.04-1.85Missed-78.3Mar. 31 2023-0.98-1.02-1.07Missed-5Dec. 31 2022-1.01-1.06-0.92Beat13.2This summary was machine generated March 5 at 11:01 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2517499726"}